NICE no for Roche's Avastin for breast cancer
This article was originally published in Scrip
Executive Summary
NICE, the National Institute for health and Clinical Excellence, said in draft guidance on 9 July that it was not inclined to recommend Roche's VEGF-targeted Avastin (bevacizumab), in combination with a taxane, as a first line treatment for metastatic breast cancer for NHS patients in England and Wales.